1626

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Pa	perwork Reduction Act of 1995,	no persons	Application Number	ı	ormation unless it displays a valid OMB control numbe	
TRANSMITTAL TRANSMITTAL FORM (to the used for all correspondence after initial filing)			Filing Date	April 18, 2000		
			First Named Inventor		James T. Loch III	
		ilina)	Art Unit	O9/529,654 April 18, 2000 James T. Loch III 1626 Sonya N. Wright A2090-1P US		
		97	Examiner Name			
	Pages in This Submission		Attorney Docket Number	A20	90-1P US	
		ENCL	OSURES (Check all th	at apply	<u> </u>	
Fee Tran	smittal Form		Drawing(s)		After Allowance Communication to Group	
_	After Final Affidavits/declaration(s)		Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation		Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group	
X Amendm					(Appeal Notice, Brief, Reply Brief) Proprietary Information	
A						
_			Change of Correspondence Add Ferminal Disclaimer	dress	ess Status Letter Other Enclosure(s) (please Identify below):	
=	n of Time Request		Request for Refund		identity below).	
Express	Abandonment Request		•			
Informati	on Disclosure Statement	السسا	CD, Number of CD(s)			
Certified Docume	Copy of Priority nt(s)	Rema	rks			
	se to Missing Parts/ ete Application					
	Response to Missing Parts Inder 37 CFR 1.52 or 1.53	i				
	SIGNA	TUDE (OF APPLICANT, ATTOR	NEV (OR AGENT	
Firm	Sidiva	TOTIL	A I LIOAN, A I ON			
or Individual	Kenneth F. Mirche	:11				
Signature	1241	SH	sell			
Date		Eds	202003			
	C	ERTIFIC	CATE OF TRANSMISSION	ON/MA	ILING	
		acsimile tra	nsmitted to the USPTO or deposite	d with the	United States Postal Service with sufficient postage a	
I hereby certify that first class mail in a	it this correspondence is being f an envelope addressed to: Com	missioner fo	or Patents, Washington, DC 20231 of	on this dat	te: 02/20/2003	
I hereby certify that first class mail in a	an envelope addressed to: Com	missioner fo	r Patents, Washington, DC 20231 (on this dat	Date FEB, 20, 2003	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U S Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



AstraZeneca Docket No. A2090 P US OFFICE

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of:

Loch III, et al.

Application Number:

09/529,654 April 18, 2000

Filed: For:

Novel Arylkyl Amines of Sprofuropyridines

Useful in Therapy

Group Art Unit: 1626

Examiner: Wright, Sonya N.

Assistant Commissioner for Patents Washington, DC 20231

INTRODUCTORY COMMENTS

Sir:

Applicants hereby respond to a Final Office Action dated 11/29/2002 which set a three month period for filing a response. This response is filed within three months of the date of the aforementioned Notice.

In this response Applicants request amendment of the claims solely to put the amended claims in condition for allowance (see remarks below).

FEES

Any fees required for filing this response are to be charged to Deposit Account 26-0166.

AMENDMENT

In the Claims:

Applicants request cancellation of Claims 2-3, 6, 9-10, 13, 16, 42 and 43 all without prejudice.

Applicants request entry of AMENDED claims 1, 4, 5, 7, 8, 11, 12 and 14 as follows:

To shake a st